ATM,BCL2, andTGFβGene Polymorphisms as Radiotherapy Outcome Biomarkers in Head and Neck Squamous Cell Carcinoma Patients

Agostini, Lidiane Pignaton; Stur, Elaine; García, Francisco Debesa; Ventorim, D.P.; Reis, Ruth; Dettogni, Raquel Spinassé; Santos, Eldamária V. W. dos; Peterle, Gabriela Tonini; Maia, L.L.; Mendes, Suzanny Oliveira; Carvalho, Marcos Brasilino de; Tajara, Eloíza H.; Paula, Fabiana Martins de; Santos, Marcelo dos; Silva, Adriana M A da; Louro, Iúri Drumond

doi:10.1089/gtmb.2017.0180

Cited by 10 publications

(16 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the key prognostic markers for survival, epidermal growth factor receptor (EGFR), cyclin D1(CCND1), ERCC1, p16, human papillomavirus (HPV), and B‐cell lymphoma‐extra large (Bcl‐xL)/Bcl‐2, as well as the amplification of genes including EMS1 , FGFR1 , and CCND1 have demonstrated some evidence in clinical trials. Others are slower to advance in clinical development because of unconvincing data and few published studies; for example, acetylcholinesterase(AchE), SNPs of specific genes, glutathione S‐transferase (GST), CD44, amplification of specific genes, hypoxic markers, KLK‐6, and MDA‐7/IL‐24; although, this does not preclude them from future investigations and clinical utility.…”

Section: Biomarkers In Hnscc Tumor Tissuesmentioning

confidence: 99%

“…Bcl‐2 is another example; evidence suggests that this marker may contribute to distant failure in HNSCC patients receiving platinum‐based CCRT . In addition, GSTs—that appear to play an essential role in the cell's defense against toxic substances—may predict platinum resistance in HNSCC .…”

Section: Biomarkers In Hnscc Tumor Tissuesmentioning

confidence: 99%

“…115 Bcl-2 is another example; evidence suggests that this marker may contribute to distant failure in HNSCC patients receiving platinum-based CCRT. 19,51 In addition, GSTsthat appear to play an essential role in the cell's defense against toxic substances-may predict platinum resistance in HNSCC. 54 MRP2 protein expression and RB protein expression were also found to be independently associated with reduced local control in patients who received CCRT.…”

Section: Predictive Tissue Markers For Platinumbased Therapymentioning

confidence: 99%

“…In most studies, baseline biomarkers are evaluated for their prognostic role for disease outcomes (regardless of treatment), reflected by critical clinical trial endpoints. Key endpoints include overall survival (OS), progression‐free survival (PFS), disease‐free survival (DFS), loco‐regional (LR) control, and distant metastasis‐free survival …”

Section: Prognostic and Predictive Biomarkersmentioning

confidence: 99%

“…FGFR1,22 and CCND1 91-93 have demonstrated some evidence in clinical trials. Others are slower to advance in clinical development because of unconvincing data and few published studies; for example, acetylcholinesterase(AchE),64 SNPs of specific genes,19 glutathione S-transferase (GST),54 CD44,61 amplification of specific genes, 32 hypoxic markers, 35,94 KLK-6,60 and MDA-7/IL-24 72 ; although, this does not preclude them from future investigations and clinical utility.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Hsieh

Wang

et al. 2019

Head & Neck

View full text Add to dashboard Cite

Background Biomarkers in head and neck squamous cell carcinoma (HNSCC) emerge rapidly in recent years, especially for new targeted therapies and immunotherapies. Methods Recent, relevant peer‐reviewed evidence were critically reviewed and summarized. Results This review article briefly introduces essential biomarker concepts, including purposes and classifications (predictive, prognostic, and diagnostic markers), and the phases of biomarker development. We summarize current biomarkers in order of clinical utility; p16 and human papillomavirus status remain the most important and validated biomarkers in HNSCC. The rationale for biomarker study design continues to evolve with technological advances, especially whole‐exome or whole‐genomic sequencing. Noninvasive body fluid and liquid biopsy biomarkers appear to hold strong potential for development as tools for early cancer detection, cancer diagnosis, monitoring of disease recurrence, and outcome prediction. In light of discrepancies among different technologies, standardized approaches are needed. Conclusion Biomarkers from cancer tissue or blood in HNSCC could direct new anticancer therapies.

show abstract

Section: Biomarkers In Hnscc Tumor Tissuesmentioning

confidence: 99%

Section: Biomarkers In Hnscc Tumor Tissuesmentioning

confidence: 99%

Section: Predictive Tissue Markers For Platinumbased Therapymentioning

confidence: 99%

Section: Prognostic and Predictive Biomarkersmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Hsieh

Wang

et al. 2019

Head & Neck

View full text Add to dashboard Cite

show abstract

Construction of a necroptosis‐related lncRNA signature to predict the prognosis and immune microenvironment of head and neck squamous cell carcinoma

Huang

Teh

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Previous studies have determined that necroptosis‐related genes are potential biomarkers in head and neck squamous cell carcinoma (HNSCC). Herein, we established a novel risk model based on necroptosis‐related lncRNAs (nrlncRNAs) to predict the prognosis of HNSCC patients. Methods Transcriptome and related information were obtained from TCGA database, and an nrlncRNA signature was established based on univariate Cox analysis and least absolute shrinkage and selection operator Cox regression. Kaplan–Meier analysis and time‐dependent receiver operating characteristic (ROC) analysis were used to evaluate the model, and a nomogram for survival prediction was established. Gene set enrichment analysis, immune analysis, drug sensitivity analysis, correlation with N6‐methylandenosin (m6A), and tumor stemness analysis were performed. Furthermore, the entire set was divided into two clusters for further discussion. Results A novel signature was established with six nrlncRNAs. The areas under the ROC curves (AUCs) for 1‐, 3‐, and 5‐year overall survival (OS) were 0.699, 0.686, and 0.645, respectively. Patients in low‐risk group and cluster 2 had a better prognosis, more immune cell infiltration, higher immune function activity, and higher immune scores; however, patients in high‐risk group and cluster 1 were more sensitive to chemotherapy. Moreover, the risk score had negative correlation with m6A‐related gene expression and tumor stemness. Conclusion According to this study, we constructed a novel signature with nrlncRNA pairs to predict the survival of HNSCC patients and guide immunotherapy and chemotherapy. This may possibly promote the development of individualized and precise treatment for HNSCC patients.

show abstract

Recent progress of biomarkers in oral cancers

Liang

Lin

Chiang

et al. 2021

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Oral cancers are the seventh most common cancer globally. While progresses in oral cancer treatment have been made, not all patients respond to these therapies in the same way. To overcome this difficulty, numerous studies have been devoted to identifying biomarkers, which enable early identification of patients who may benefit from a particular treatment modality or at risk for poor prognosis. Biomarkers are protein molecules, gene expression, DNA variants, or metabolites that are derived from tumors, adjacent normal tissue or bodily fluids, which can be acquired before treatment and during follow-up, thus extending their use to the evaluation of cancer progression and prediction of treatment outcome. In this review, we employed a basic significance level (<0.05) as the minimal requirement for candidate biomarkers. Effect sizes of the biomarkers in terms of odds ratio, hazard ratio, and area under the receiver operating characteristic curves were subsequently used to evaluate the potential of their clinical use. We identified the CCND1 from the tumor, human papillomavirus, HSP70, and IL-17 from the peripheral blood, and high density of CD45RO+ tumor-infiltrating lymphocytes as the clinically relevant biomarkers for oral cancers.

show abstract

ATM,BCL2, andTGFβGene Polymorphisms as Radiotherapy Outcome Biomarkers in Head and Neck Squamous Cell Carcinoma Patients

Cited by 10 publications

References 25 publications

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Construction of a necroptosis‐related lncRNA signature to predict the prognosis and immune microenvironment of head and neck squamous cell carcinoma

Recent progress of biomarkers in oral cancers

Contact Info

Product

Resources

About